Background {#Sec1}
==========

Tuberculosis (TB), caused by *Mycobacterium tuberculosis*, is an infectious disease that poses a major global public health problem for both developing and developed countries. The World Health Organization (WHO) estimates that in 2015, 1.8 million people died from TB (including 0.4 million who were HIV-positive) \[[@CR1]\]. In the same year, more than 95% of TB deaths occurred in low- and middle-income countries, and 170,000 children died of TB (excluding children with HIV) \[[@CR1]\].

The usual site of TB infection is the lungs (pulmonary TB), but other organ systems can be involved (extrapulmonary TB) in spreading *M. tuberculosis*, including: pleural, lymphatic, urogenital, osteoarticular. The frequency of extrapulmonary disease increases with immune deficiency states, such as acquired immune deficiency syndrome patients (in whom extrapulmonary disease accounts for 50--60%) \[[@CR2]\], or by the dissemination of *M. tuberculosis* throughout multiple organ systems (Miliary TB) \[[@CR3]\]. Rapid and early diagnosis of TB and initiating optimal treatment would not only enable a cure of an individual patient but will reduce future numbers of TB cases \[[@CR4]\].

The most widely used TB diagnostic test, microscopic examination of sputum for acid-fast bacilli (AFB), takes less than an hour; however, it is costly, lacks sensitivity and specificity, especially in HIV-infected individuals and children \[[@CR5], [@CR6]\]. Moreover, a positive result by this test does not discriminate between the *Mycobacterium* species \[[@CR7]\]. Otherwise, Lowenstein-Jensen culture, generally used as the gold standard in suspected pulmonary cases, is more sensitive than smear microscopy, but it is time consuming (may take 4--8 weeks in solid media culture), and it requires adapted infrastructures and well-trained laboratory staff \[[@CR8]\], which can delay effective medical interventions; therefore, the need for new rapid and accurate diagnostic methods has emerged. With the rapid evolution of molecular techniques, a wide variety of nucleic amplification tests (NAATs) such as polymerase chain reaction (PCR), real-time PCR, and loop-mediated isothermal amplification (LAMP), are available for the diagnosis of TB*.*

Currently, more than 50 new TB tests are in various stages of development \[[@CR9]\]. Although the laboratory-developed and commercial NAATs assays have been primarily developed for the analysis of respiratory specimens, they are often used in non-respiratory specimens to the diagnosis of extra-pulmonary TB \[[@CR10]--[@CR12]\], because no commercial assay is approved for this purpose.

The present review summarizes the existing bibliography of molecular diagnostics tests for detection of TB. This is not an exhaustive review of all commercial NAATs; rather, the review presents the molecular techniques that have been used for detection of *M. tuberculosis* in clinical specimens. Some of them are already incorporated into the routine diagnostic, while other promising tests are still undergoing evaluation. .

Rapid molecular tests incorporated into the routine diagnostic laboratory {#Sec2}
-------------------------------------------------------------------------

### COBAS TaqMan MTB {#Sec3}

The qualitative COBAS TaqMan MTB (TaqMan MTB; Roche Diagnostics, Tokyo, Japan) test has also been introduced to replace the well-established COBAS Amplicor assay \[[@CR13]\]. COBAS TaqMan MTB (CTM) test is a real-time PCR assay that amplifies part of the 16S rRNA gene with the use of a TaqMan probe for the detection of MTB complex DNA in clinical specimens. The turnaround time for analyzing 48 samples simultaneously using COBAS TaqMan is 2.5 h \[[@CR14]\]. The COBAS TaqMan MTB assay is approved by the US Food and Drug Administration (FDA) for use in smear-positive and/or smear-negative pulmonary disease. The manufacturer's instructions limit CTM application to respiratory specimens only \[[@CR15]\]. However, many studies have evaluated the performance of the CTM assay for non-respiratory specimens \[[@CR16]--[@CR19]\].

The diagnostic accuracy of the CTM was poorer for the non-respiratory specimens than for the respiratory specimens. Bloemberg et al. \[[@CR17]\] examined 838 respiratory specimens and found Cobas TaqMan MTB assay to have 88.4% sensitivity and 98.8% specificity, compared to a sensitivity of 63.6% and a specificity of 94.6% for the 305 non-respiratory specimens. While using culture as the golden standard for all specimens, the sensitivity and specificity was 82.4% and 97.7% respectively.

Studies have found that the Cobas assay had higher sensitivity in smear-positive specimens than in smear-negative specimens \[[@CR20]\], which might be attributable to the decontamination and concentration steps \[[@CR21]\]. The sensitivity of the assay ranges from 96.9% to 98% in smear-positive samples and from 34.9% to 79.5% in smear-negative samples, while the specificity ranges from 78.1% to 100% in smear-positive samples and from 98.7% to 99% in smear-negative samples \[[@CR17]--[@CR19], [@CR22]--[@CR24]\]. However, these results vary from study to study. Some studies have suggested that this variance is due to the acid-fast bacilli (AFB) smear status, variable specimen types and incidence of TB \[[@CR19], [@CR20]\]. The results of the Cobas TaqMan MTB assay should be carefully interpreted alongside the clinical data.

### Loop-mediated isothermal amplification {#Sec4}

Loop-mediated isothermal amplification (LAMP) (Eiken Chemical Co. Ltd., Tokyo, Japan) assay is an isothermal molecular method developed by Notomi et al. \[[@CR25]\]. LAMP has been successfully implemented in nucleic acid research, and in clinical application as a screening tool \[[@CR26]\]. Several LAMP-based assays have been developed to detect *M. tuberculosis* infection, targeting *gyrB* \[[@CR27]\], *rrs* \[[@CR28]\], *rimM* \[[@CR29]\], *IS6110* \[[@CR30]\], *hspX* \[[@CR31]\], *mpb64* \[[@CR32]\] and *sdaA* gene \[[@CR33]\].

LAMP is an isothermal nucleic acid amplification technique, in which amplification is carried out at a constant temperature without the need for a thermal cycler. This method amplifies very few copies of target DNA with high specificity, efficiency, and rapidity under isothermal conditions using a set of 4 specially designed primers and a DNA polymerase with strand displacement activity \[[@CR25], [@CR34], [@CR35]\]. LAMP was recommended by WHO in August 2016 for diagnosing pulmonary TB in adults as a potential replacement for smear microscopy.

Many studies show that LAMP offers potential advantages over PCR for its simplicity, speed, specificity and cost-effectiveness. These studies favor its use in simplified testing systems, which could be appropriate in settings with limited resources \[[@CR2], [@CR35]\].

TB-LAMP has higher sensitivity for smear-positive samples (92.1%--100%) than for smear-negative samples (52.1%--90.3%) \[[@CR36]--[@CR39]\]. For extrapulmonary samples, a recent study found that LAMP had a good sensitivity (95.6%) compared to 3 conventional methods: liquid culture, solid culture, and smear microscopy (69.6%, 65.2% and 17.4%, respectively) \[[@CR40]\]. It has been observed that the exposure of reaction tubes to aerosol contamination was identified as one of the possible causes of false-positives results \[[@CR29]\].

In the policy guide, WHO excluded all data obtained from extra pulmonary samples, and the validation of TB-LAMP testing with extra pulmonary samples is still under investigation \[[@CR41]\]. To date, LAMP has not been fully evaluated in HIV patients and children (no data have been published for children samples).

### Gene Xpert TB assays {#Sec5}

Xpert MTB/RIF (Xpert; Cepheid Inc., Sunnyvale, California, United States of America \[USA\]) is an automated polymerase chain reaction (PCR) test utilizing the GeneXpert platform \[[@CR42], [@CR43]\]. The Xpert MTB/RIF assay detects MTB and rifampicin resistance within two hours of starting the test, with minimal hands-on technical time \[[@CR44]\]. It has been approved by the WHO and the US (FDA) (Table [1](#Tab1){ref-type="table"}) \[[@CR45]--[@CR47]\]. The test procedure may be used directly on clinical specimens, either raw sputum samples or sputum pellets, and samples created after decontaminating and concentrating the sputum \[[@CR42]\]. Several studies reported that Xpert MTB/RIF is a sensitive method for rapid diagnosis of TB, compared to conventional techniques \[[@CR48], [@CR49]\].Table 1Characteristics of approved (WHO and/or FDA) molecular assays for rapid detection of MTB and drug-resistanceTest specificationCOBAS TaqMan MTBTB-LAMPXpert MTB/RIFXpertMTB/RIF UltraGenoType MTBDR*plus*GenoType MTBDR*sl*ManufacturerRoche DiagnosticsEiken Chemical CoCepheidCepheidHain LifescienceHain LifescienceTechnologyReal-time PCRLoop-mediated Isothermal amplification (LAMP)Real-time PCR (molecular beacons)Real-time PCR (molecular beacons)Multiplex PCR + reverse hybridizationMultiplex PCR + reverse hybridizationDetectsMTBMTBMTB + RIF resistanceMTB + RIF resistanceMTB + resistance to RIF and INHMTB diagnosis + resistance to FLQ and SLIDTarget16S rRNA*IS6110rpoB* gene*rpoB* gene*rpoB, katG, inh* genes*gyrA, rpo, rrs, eis* genesTime to results2.5 h\< 1 h \[[@CR41]\]2 h \[[@CR43]\]\< 90 min \[[@CR58]\]5 h5 hApproval statusFDAWHOWHOWHOWHOWHORecommandationsAs a confirmatory test, on smear-positive specimensAs a replacement for smear microscopy in adults or a follow-on test to smear microscopy in adults (when further testing of sputum smear-negative specimens is necessary) \[[@CR41]\]As the initial diagnostic test for tuberculosis in patients (adults and children) suspected of having active TB disease with either multidrug-resistant TB or HIV-associated TB \[[@CR47]\]As a replacement of Xpert MTB/RIF due to its greater sensitivity in detecting MTB \[[@CR66]\]As the initial test instead of phenotypic culture-based DST to detect resistance to RIF and INH, in persons with a sputum smear-positive specimen or a cultured isolate of MTBC, from both pulmonary and extrapulmonary sites \[[@CR73]\].For patients with confirmed RIF-R TB and/or MDR TB as the initial test, instead of phenotypic culture-based DST, to detect resistance to FLQ and SLID \[[@CR83]\]Benefits− Does not require expensive instruments and laboratory environments- Requires minimal expertise\
- Speed and cost effective- Requires minimal expertise\
- Excellent sensitivity in tests of smear-positive sputum samples− Improve detection of mutants at codon 533 \[[@CR58]\]\
− Differentiate silent mutations at codons 513 and 514 \[[@CR58]\].\
- Detect a hetero-resistant sample \[[@CR58]\]- High sensitivity for detection of RIF resistance.- High sensitivity and specificity for detection of FLQ and SLID resistance \[[@CR84]\].Limitations- Exhibits heterogeneous performance from study to study \[[@CR24]\]\
- Does not screen for any markers of drug resistance− Requires several manual steps.\
− Inferior performance in smear negatives sputum samples \[[@CR102]\]\
− False positives results due to aerosol contamination \[[@CR29]\]\
− Does not screen for any markers of drug resistance- High costs and sophisticated hardware.\
- Low sensitivity in smear-negative pulmonary samples and special populations (HIV-positives, children, extrapulmonary TB).\
- Do not accommodate all mutations conferring resistance to anti-TB agents \[[@CR58]\]− Low specificity in patients with a recent history of TB treatment or from high-incidence countries \[[@CR61]\].\
− Should not be used as a replacement test for culture in children \[[@CR65]\]\
− Do not accommodate all mutations conferring resistance to anti-TB agents \[[@CR61]\]− Over diagnose the presence of MTB complex DNA in culture-negative samples \[[@CR81]\].\
− Low sensitivity to detect INH resistance.\
− Complexity, the number of steps.\
− Requires training for interpretation of results\
− Do not perform well when applied to paucibacillary clinical specimens\
− Do not accommodate all mutations conferring resistance to anti-TB agents− Not optimal to detect resistance to KAN \[[@CR84]\] and ethambutol \[[@CR86]\].\
− Low sensitivity in smear-negative samples \[[@CR76]\].\
− Do not accommodate all mutations conferring resistance to anti-TB agents \[[@CR84]\].Price per testNot availableUS\$ 6US\$ 9.98US\$ 9.98US\$10US\$10US\$: United States dollarshrs: hoursmin: minutes

Studies evaluating Xpert performance in pulmonary and extrapulmonary samples in low and intermediate prevalence settings \[[@CR49], [@CR50]\], showed a sensitivity ranging from 47.8% to 73% and from 28.2% to 73.2% for smear-negative pulmonary specimens and smear-negative extrapulmonary specimens, respectively. The sensitivity of Xpert MTB/RIF in smear-positive samples was 100% \[[@CR49], [@CR50]\]. The Xpert MTB/RIF assay is less sensitive than liquid cultures for the detection of MTB in both children and adults \[[@CR51], [@CR52]\]. Xpert has generally performed very well as a rapid test for rifampicin resistance (RIF-R), with a pooled sensitivity and specificity of 94% and 98%, respectively \[[@CR44]\] (Table [2](#Tab2){ref-type="table"}). However, the ability of the assay to detect the RIF-R in a sample with mixtures of RIF-susceptible and RIF-sensitive *M. tuberculosis* populations is dependent on the type of mutation present \[[@CR42]\].Table 2Sensitivity and specificity of endorsed molecular assays for rapid detection of drug-resistant TBAssayDetection of drug resistanceSensitivity %\
(95% confidence interval)Specificity %\
(95% confidence interval)ReferencesXpert MTB/RIFRIF95 (90--97)98 (97--99)44\*Xpert UltraRIF92.7 (80.1--98.5)98 (92.8--99.9)58\*GenoType MTBDR*plus*RIFSmear positive sample: 88.2 (72.6--96.7)Smear positive sample: 89.5 (75.2--97.1)77\*Smear negative and culture positive direct sample: 100 (29.2--100)Smear negative and culture positive direct sample: 63.6 (30.8--89.1)INHSmear positive sample: 91.7 (77.5--98.3)Smear positive sample: 97.2 (85.5--99.9)Smear negative and culture positive direct sample: 60 (14.7--94.7)Smear negative and culture positive direct sample: 100 (66.4--100)MDR-TB (RMP&INH)Smear positive sample: 96.4 (81.7--99.9)Smear positive sample: 100 (88.8--100)Smear negative and culture positive direct sample: 100 (15.8--100)Smear negative and culture positive direct sample: 100 (47.8--100)GenoType MTBDR*sl*FLQ100 (95.8--100)98.9 (96.1--99.9)84\*AMK93.8 (79.2--99.2)98.5 (95.5--99.7)KAN89.2 (79.1--95.6)98.5 (95.5--99.7)CPM86.2 (68.3--96.1)95.9 (92.2--98.2)44\*: reference standard was phenotypic culture-based DST58\*: results were compared with phenotypic susceptibility testing and Xpert MTB/RIF77\*: results were compared with the conventional liquid culture based reference standard method, BACTEC MGIT 960 culture and DST84\*: results were compared with phenotypic DST

Several studies have found that Xpert MTB/RIF was not capable of detecting resistance-conferring mutations located outside the 81 bp rifampicin resistance determining region (RRDR) of the *rpoB* gene \[[@CR42], [@CR53]\]. Results obtained in Swaziland show that the Xpert MTB/RIF assay did not detect the *rpoB* I491F mutation in 38/125 (30%) of multidrug-resistant strains, as compared to DNA sequencing \[[@CR53]\]. The high frequency of the I491F mutation highlights the limits of the assay. Thus, it is important to detect this mutation and complement commercial assays for the diagnosis of RIF-R *M. tuberculosis* in routine conditions, particularly in countries where this specific mutation is frequent \[[@CR54]\].

The second limitation of Xpert MTB/RIF compared to sequencing methods is that Xpert can not differentiate silent mutations emerging at various positions in the RRDR of the *rpoB* gene \[[@CR55]\]. These missed mutations within the RRDR, together with those outside the RRDR, may cause misinterpretation of RIF susceptibility, rendering treatment ineffective and may be untraceably circulated through chains of transmission.

Luetkemyer et al. and Parcell et al. \[[@CR56], [@CR57]\] showed in their studies that the performance of Xpert MTB/RIF did not differ between higher- and low-prevalence areas. For HIV-associated TB, Xpert MTB/RIF has lower sensitivity \[[@CR44]\].

To improve the sensitivity and specificity of the current assay in detection of TB and RIF-R, respectively, a new version of the Xpert MTB/RIF assay, called Xpert Ultra, has been developed. The Xpert MTB/RIF Ultra was designed by adding two amplification targets (IS*6110* and IS*1081*), 25 different RRDR mutations covering almost the entire *rpoB* RRDR from codons 510 to 533, doubling the size of the DNA delivered to PCR reaction, and other technical enhancements to reduce the limits of detection from 112.6 CFU/mL of sputum for Xpert to 15.6 CFU/mL of sputum for Ultra \[[@CR58]\].

In 2015, Alland et al. \[[@CR59]\] found that Xpert MTB/RIF Ultra is much more sensitive than Xpert, and is likely to be as sensitive as liquid TB culture. The multi-center study (1520 person with signs or symptoms of pulmonary TB) carried out by the Foundation for Innovative New Diagnostics (FIND) \[[@CR60]\] revealed that compared to culture the sensitivity of Ultra was 5% higher than that of Xpert MTB/RIF (87.8% vs 82.9%), but the specificity was 3.2% lower (94.8% vs 98%). In the same study, the sensitivity of Ultra was 17% higher than Xpert MTB/RIF in people with smear-negative, culture positive TB (61.3% vs 44.5%) and 12% higher in HIV-infected patients (87.8% vs 75.5%).

The higher sensitivity of Ultra is accompanied by a loss of specificity, particularly among individuals with a history of previous TB treatment \[[@CR61]\]. Arend and van Soolingen \[[@CR62]\] reported that the excess of false positive Xpert Ultra results found by Dorman et al. \[[@CR61]\] can be explained by detection of DNA from non-viable *M tuberculosis*, a phenomenon previously shown for Xpert MTB/RIF \[[@CR63]\].

In a study of 378 children, Ultra's sensitivity was 24% higher than that of MTB/RIF \[[@CR64]\]. A recent study performed in South African children (367 children) hospitalized with suspected pulmonary TB, has shown that Ultra detected 75.3% of culture-confirmed cases. The authors concluded that Ultra should not be used as a replacement test for culture in children \[[@CR65]\].

The rates of detection of RIF susceptibility were comparable between Xpert and Ultra \[[@CR58]\]. Ultra improved detection of mutants at codon 533, differentiated silent mutations at codons 513 and 514, and detected a hetero-resistant sample that was missed by both phenotypic susceptibility testing and Xpert \[[@CR58]\]. However, mutations such as IIe491Phe are not detected by Xpert Ultra \[[@CR61]\].

At the end of March 2017, the WHO recommended the replacement of Xpert by Xpert MTB/RIF Ultra, based on its increased sensitivity compared to Xpert, which could improve the diagnosis of paucibacillary forms of TB disease such as childhood TB, HIV-associated TB, or extrapulmonary TB \[[@CR66]\].

Cepheid is also slated to release another major technology improvement called the GeneXpert Omni for point-of-care testing for TB and rifampicin resistance, using the same cartridges as those used in the current GeneXpert machine. GeneXpert Omni is a portable single-cartridge testing unit, less expensive than the current Genexpert, and has four hours of battery life. Because of the above-mentioned characteristics, it is very useful, particularly in remote settings where very limited infrastructure is available for rapid diagnosis of TB. The projected release of the Omni in emerging markets is at the end of 2018, and it has yet to be launched or evaluated by the WHO \[[@CR67]\].

Cepheid Inc. is also currently developing another cartridge, the Xpert XDR, which will provide resistance to isoniazid, fluoroquinolones and aminoglycosides \[[@CR68]\]. Xpert XDR may be highly useful for extensively drug-resistant tuberculosis (XDR-TB) triaging in high DR-TB settings, considering the new fluoroquinolone-based short regimens \[[@CR69], [@CR70]\].

### GenoType Line-Probe Assays {#Sec6}

Molecular detection of *M. tuberculosis* by line probe assays (LPA) was introduced in 1995. The assay also allows for rapid detection of drug resistance \[[@CR71]\]. LPA, known as solid-phase hybridization assays, involves a series of steps including: extraction of DNA from cultures or directly from clinical samples, PCR amplification of nucleic acid sequences, denaturation, hybridization of the biotinylated PCR amplicons with oligonucleotide probes immobilized on a strip and colorimetric development that allows for lines to be seen where the probes are located \[[@CR72]\]. Some of these LPA tests are INNO-LiPA Mycobacteria (Innogenetics, Belgium) for the distinction of the *M. tuberculosis* (sub) species and the most frequently encountered nontuberculous mycobacteria, and Genotype MTBDR*plus* and GenoType MTBDR*sl* (Hain LifeScience GmbH, Nehren, Germany) for rapid detection of MTB and its associated drug resistance, as discussed above.

The Genotype *M. tuberculosis* drug resistant (MTBDR) *plus* (Version 2.0) is a qualitative in vitro test for detection of the *M. tuberculosis* complex and simultaneous detection of mutation in the *rpoB* and *katG* genes for rifampicin (RIF) and isoniazid (INH) resistance, respectively, and its use is approved by WHO \[[@CR73]\]. This test can be used on bacterial cultures or smear-positive clinical specimens and takes approximately 5.5 h to perform \[[@CR74]\]. Many studies confirm that the diagnostic performance of Genotype MTBDR*plus* (Version 2.0) LPA for detection of multidrug-resistant tuberculosis (MDR-TB) in direct smear-positive sputum sample was highly sensitive and specific \[[@CR75]--[@CR77]\]. However, the sensitivity of the assay should be improved for detection of MDR-TB in direct smear-negative sputum specimens \[[@CR77]\].

In a study conducted on 242 multidrug-resistant and 30 pansusceptible *M. tuberculosis* isolates, the performances of the LPA and DNA sequencing in detecting RIF and INH resistance-associated mutations were compared to that of a conventional agar proportion DST. The results show that the sensitivity for detection of MDR-TB was 78.5% with the GenoType MTBDR*plus* test and 91.3% by resistance gene sequencing \[[@CR78]\]. The specificity for RIF resistance, INH resistance, and MDR-TB detection was 100% by both methods. However, DNA sequencing demonstrated superior performance in detecting INH resistance. The study suggested that additional alleles associated with INH resistance should be evaluated to improve the sensitivity of the GenoType MTBDR*plus* test.

In terms of diagnosis, a number of studies have demonstrated that GenoType MTBDR*plus* (Version 2.0) present greater sensitivity for detection of MTB complex DNA in smear-positive samples \[[@CR79]--[@CR81]\]. Barnard et al. \[[@CR81]\] demonstrated that GenoType MTBDR*plus* (Version 2.0) overdiagnoses the presence of *M. tuberculosis* complex DNA in culture-negative samples, which may be explained by the amplification of DNA released from nonviable bacilli, by laboratory cross-contamination, or by a transcription error. Further research evaluating the effect of smear status, smear grade and other covariates such as HIV on the diagnostic accuracy of GenoType MTBDR*plus* (Version 2.0), for detection of *M. tuberculosis* complex DNA is needed.

Another LPA, the GenoType MTBDR*sl* 2.0 (Hain LifeScience GmbH, Nehren, Germany) line probe assay was developed for the detection of *M. tuberculosis* and simultaneous detection of resistance-conferring mutations of fluoroquinolones (FLQ) (*gyrA* and *gyrB* genes) and second-line injectable drugs (SLID) (*rrs* and *eis* genes) \[[@CR82]\]. The target region for detection of ethambutol (EMB) (a first-line anti-tuberculosis drug) resistance (*embB* codon 306), present in MTBDR*sl* v1, has been removed from v2.0. WHO recommended the use of the GenoType MTBDR*sl* 2.0 assay as an initial test, instead of phenotypic culture-based drug susceptibility testing (DST), to detect FLQ and SLID resistance in confirmed RIF-R and MDR patients \[[@CR83]\].

Gardee and colleagues \[[@CR84]\] reported that GenoType MTBDR*sl* 2.0 has shown an improvement in sensitivity and specificity for the determination of molecular resistance to both FLQ (100% and 98.9%) and SLID (89.2% and 98.5%) (Table [2](#Tab2){ref-type="table"}). The same study confirmed the presence of *gyrA* mutations missed by the assay, which were detected by whole-genome sequencing (WGS).

It has been reported by several authors \[[@CR85], [@CR86]\] that MTBDR*sl* v1 showed poor accuracy for detecting resistance to EMB (55% and 71%) compared to FLQ and SLID. Only mutations covered by wild-type or mutant probes can be detected. Other mutations are required to be targeted by the assay to increase sensitivity and specificity.

Later-stage or marketed tuberculosis diagnostic test candidates {#Sec7}
---------------------------------------------------------------

Several new diagnostics are emerging from the development pipelines, and currently more than 50 new TB tests are in various stages of development \[[@CR9]\]. The majority of the tools in the pipeline are still in early stages of development and/or evaluation. A few new technologies are available on the market where the data are unavailable or limited \[[@CR87]\]. Among the assays marketed without any/or a few data published are EasyNAT TB (Ustar Biotechnologies, Hangzhou, China), FluoroType MTB (Hain Lifesciences GmbH, Nehren, Germany) and PURE-LAMP (Eiken Chemical Company, Japan) (Table [3](#Tab3){ref-type="table"}).Table 3characteristics of molecular assays for rapid detection of MTB and drug-resistance, not yet approved by WHO and/or FDATest specificationPURE TB-LAMPFluoroType MTBEasyNAT TBXpert OmniXpert XDRManufacturerEiken Chemical CoHain LifescienceUstarCepheidCepheidTechnologyProcedure for Ultra Rapid Extraction Loop-mediated isothermal amplificationReal-time PCR (HyBeacon fluorescence)Isothermal DNA amplification\
Lateral flowReal-time PCR (molecular beacons)Real-time PCR (molecular beacons)DetectsMTBMTBMTBMTB + RIF resistanceMTB + resistance to INH, FLQ and SLIDTime to results90 min \[[@CR90]\]3 h90 min∼ 110 min \[[@CR67]\]90 minCurrent statusThe assay is now on path for WHO reviewCE-IVD markedCE-IVD certified\
Approved by China FDAPlatform under development. Launch expected at the end of 2018.Assay under development.Benefits− Performed quickly \[[@CR36]\].\
− No sophisticated laboratory equipment is needed \[[@CR36]\].\
− Requires fewer procedures and consumables.\
− Sensitivity higher than smear microscopy \[[@CR36]\]− Fluorocycler system is suitable for low number of samples or for large series \[[@CR92]\].\
− Sensitivity equivalent to other molecular tests.− Requires basic laboratory equipment− Point of care\
− Performed quickly \[[@CR95]\].Assay under development.Limitations− Yield false-negative results \[[@CR90]\]\
− Possible risks for cross contamination.\
− Does not screen for any markers of drug resistance.\
− Further studies are required \[[@CR98]\].− Low specificity due to DNA contamination \[[@CR94]\]\
− Low sensitivity in smear-negative \[[@CR92]\].\
− Does not screen for any markers of drug resistance.\
- Further studies are required \[[@CR92]\].− Not suitable for diagnosis of extrapulmonary TB \[[@CR100]\].\
− Does not screen for any markers of drug resistance.− Processes one sample at a time \[[@CR95]\]\
− Cost and accessibility will limit adoption in high-endemic areas\
− Do not accommodate all mutations conferring resistance to anti-TB agentsAssay under development.Price per testNot availableNot availableUS\$ 6--8Not availableNot available

### Pure-LAMP {#Sec8}

The PURE (Procedure for Ultra Rapid Extraction)-LAMP (Eiken Chemical, Tokyo, Japan) is a manual TB detection tool based on loop-mediated isothermal amplification (LAMP) using a nucleic acid amplification method, developed from 2007 to 2010, by Chemical Company and FIND. LAMP with the PURE test can be performed quickly (within 90 min) and includes three steps, sample preparation, amplification with LAMP and visual detection of fluorescence light from the reaction tube using UV light \[[@CR36], [@CR88]\].

Several studies showed that PURE-LAMP has very high sensitivity and specificity, which makes it economic, cost effective and rapid method for the diagnosis of tuberculosis \[[@CR8], [@CR89]\]. Mitarai et al. \[[@CR88]\] reported the sensitivity of PURE-LAMP in smear-negative TB patients to be 55.6%, and 98.2% among smear positive TB patients. Ou et al. \[[@CR36]\] reported that the sensitivity of the PURE-LAMP in smear-negative TB patients and culture-positive TB patients was 53.81%, the overall sensitivity was 70.67% and the specificity of PURE-LAMP was 98.32%. Kouzaki et al. \[[@CR90]\] showed that PURE-LAMP may potentially be a valuable tool for the diagnosis of extrapulmonary TB. N'guessan et al. \[[@CR8]\] compared the performances of sputum smear microscopy (SSM) after Ziehl-Neelsen staining and PURE TB-LAMP assay. The results of this study show that the sensitivity of TB-LAMP assay is higher than SSM. However, SSM specificity was higher than molecular method. Thus, PURE-LAMP is recommended along with other diagnostic methods to verify the diagnosis of TB, particularly in false-negative samples \[[@CR90]\]. The assay is now on path for WHO review.

### FluoroType MTB {#Sec9}

FluoroType MTB (Hain Lifescience, Nehren, Germany) assay is a rapid molecular diagnostic test using real-time PCR to detect *M. tuberculosis* complex from respiratory and non-respiratory clinical specimens. The FluoroType MTB test is based on the HyBeacon fluorescence technology \[[@CR91]\]. The amplification is performed on the FluoroCycler instrument (Hain Lifescience) while the detection is performed by melt curve analysis (MCA) with single stranded oligonucleotides labeled with fluorescent dyes that are complementary to the amplified DNA. The method gives results for multiple specimens within 3--4 h \[[@CR92]\].

The first evaluation study of the new FluoroType MTB assay performed for the direct detection of *M. tuberculosis* in clinical respiratory tract specimens demonstrated that sensitivity and specificity were 95.1% and 96.4%, respectively, in 661 specimens tested, and that sensitivity was 100% for smear-positive and 84.6% for smear negative specimens, respectively \[[@CR93]\]. Hofmann-Thiel and Hoffmann \[[@CR92]\], found that FluoroType MTB assay had a sensitivity of 88.1% (smear-positive 100%; smear-negative 56.3%) and a specificity of 98.9%, in comparison with culture. The authors concluded that the test results were similar to non-nucleic acid amplification tests on the market, and that the Fluorocycler system is suitable for low numbers of samples.

Recently, the system has been evaluated in resource-poor settings \[[@CR94]\]. The diagnostic accuracy of the FluoroType MTB assay was calculated using solid culture as the reference standard and described by light-emitting diode fluorescence smear positivity, HIV status and Xpert MTB/RIF. The authors found that FluoroType MTB has a sensitivity equivalent to other molecular tests and identified more culture-positive samples than Xpert MTB/RIF, but its specificity was lower than expected, due to DNA contamination during the sample preparation steps.

The assay is marketed in Europe and launched for marketing in April 2017, however it is not yet evaluated by WHO \[[@CR95]\].

### EasyNAT TB {#Sec10}

The EasyNAT TB isothermal nucleic acid amplification diagnostic kit (Ustar Biotechnologies Co. Ltd., Hangzhou, China) uses isothermal cross-priming amplification technology for the qualitative detection of *M. tuberculosis* \[[@CR96]\]. The assay was approved in 2014 for detection of pulmonary TB by the China FDA \[[@CR97]\]. To date, EasyNAT TB has been evaluated only for the detection of pulmonary TB in adults \[[@CR98], [@CR99]\].

Ou et al. and Mhimbira et al. \[[@CR98], [@CR99]\] reported sensitivity for MTB detection against culture of 84.1% and 66.7%, and specificity of 97.8% and 100%. Sensitivity in these studies was further reduced when only smear-negative but culture-positive pulmonary TB cases were tested (59.8% and 10%), suggesting further evaluation in larger study populations from different regions that are endemic for TB \[[@CR99]\].

Bholla et al. \[[@CR100]\] evaluated the performance of EasyNAT for diagnosis of extrapulmonary TB (tuberculous lymphadenitis of children), and found that the sensitivity and specificity was 19% and 100%, respectively. The authors concluded that EasyNAT is not suitable for diagnosis of extrapulmonary TB.

### Rapid whole-genome sequencing {#Sec11}

Early detection of drug resistance is crucial in choosing the most effective treatment to avert mortality of infected individuals and to prevent the risk of transmission of drug-resistant TB \[[@CR101]\]. Molecular tests such as quantitative real time amplification (e.g. Xpert MTB/RIF) and line probe assays (e.g. GenoType MTBDRplus*/sl*), although more rapid (less than a day), are able to identify only limited numbers of specific resistance mutations in drug target genes \[[@CR102]--[@CR104]\]. Both technologies lack capacity to detect mutations outside of the rifampicin resistance-determining region (RRDR) of the *rpoB* gene (e.g. I491F mutation) \[[@CR53], [@CR105]\] or to differentiate silent mutations from those that effect drug efficacy (e.g. the substitution of CGT for TTG in codon 533 of the *rpoB* gene), leading to false positive results \[[@CR106], [@CR107]\]. The ability to detect and identify such mutations among patients with TB has become necessary, and would be of tremendous value in quickly guiding the initiation of appropriate therapy. Genome sequencing has the potential to overcome these problems and can provide clinically relevant data within a time frame that can influence patient care.

The past decade has seen a considerable expansion of sequencing capacity improving its availability for routine laboratories. Whole-genome sequencing (WGS) has been shown to provide a rapid and comprehensive view of the genotype of *M. tuberculosis*, and allows simultaneous identification of all known resistance-associated loci with high concordance to culture-based drug susceptibility testing (DST), while also providing opportunities to characterize other loci as predictive of resistance or not \[[@CR108]\]. Results reported by Shea et al. \[[@CR109]\] for 462 prospectively collected *M. tuberculosis* complex strains, show that strain identification by WGS was determined to be 99% accurate, and concordance between drug resistance profiles generated by WGS and culture-based DST methods was 96% for 8 drugs (RIF, INH, FLQ, PZA, KAN, EMB, STR, ETH), with an average resistance-predictive value of 93% and susceptible-predictive value of 96%. Furthermore, WSG can be used in outbreak surveillance to understand transmission in a population \[[@CR110]\].

Despite the perceived benefits of WSG for routine diagnosis and management of drug-resistant TB, it has only been implemented in a few high-income countries, low-TB burden settings such as England \[[@CR111]\]. The implementation of WGS in the clinical setting is hindered by some limitations, including the requirement of bacterial enrichment by culturing, prior to DNA isolation and sequencing, and this generally takes at least a couple of weeks. Limited studies demonstrated the use of WSG to generate results within a shorter turnaround time. Findings from studies performed by Brown et al. \[[@CR112]\] and Nimmo et al. \[[@CR108]\] showed that WGS can be successfully performed directly from uncultured sputa.

The complexity of WGS data and its analysis also represents a significant challenge, pointing to the need of bioinformatics expertise among clinical microbiologists \[[@CR111]\]. A number of groups are now developing software to help people without bioinformatic skills to process and analyse large sets of raw data. In this context, Coll et al. \[[@CR113]\] published an exhaustive library with 1325 mutations predictive of DR for 11 anti-tuberculosis drugs (AMK, CAP, EMB, ETH, INH, KAN, MOX, OFX, PZA, RMP and STR) and developed an online tool that rapidly analyses raw sequence data and predicts resistance. However, further work will be required to clarify the current discrepancies between genotype and phenotype \[[@CR114]\], as well as the understanding of the genetic basis of antibiotic resistance, which complicates the interpretation of WGS data \[[@CR111]\].

Conclusions {#Sec12}
===========

A number of studies have highlighted the role of rapid molecular diagnostic in diagnosis, management and monitoring of TB. Compared with traditional testing methods, molecular TB diagnostics have been shown to reduce the turnaround time (the results can be obtained within hours from receipt of the specimen) with reliable results on smear-positive specimens, but have lower sensitivities especially in specimens that are negative by microscopy (and are generally less effective in children compared with adults). Furthermore, the additional cost, the need for a laboratory infrastructure (i.e. Xpert MTB/RIF), as well as the need for technicians trained in molecular techniques are limitations that pose considerable challenges, especially in low-resource settings. Despite significant advances in the development of novel tests, molecular tests cannot replace culture, but should be used in addition to conventional tests (smear microscopy, culture, and phenotypic drug susceptibility testing) and clinical data for TB diagnosis, as highlighted by other studies \[[@CR115], [@CR116]\].

Many questions remain concerning the effectiveness of NAATs for smear-negative pulmonary and extrapulmonary TB in adults, detection of paucibacillary forms of TB (e.g. pediatric disease) and previously treated individuals. Furthermore, no tests are available which are universally applicable to all patients.

Whole genome sequencing (WGS) has the potential to revolutionize the diagnosis of *M. tuberculosis* infection. However, the utility of WSG is currently limited due to the major drawbacks of sequencing, such as the costs associated with the test, the technical skill required, complex bioinformatic procedures and the unavailability of sequencing facilities. There are currently no plans for routine implementation of WSG in resource-limited, high-TB burden countries.

Research work must continue towards developing new molecular and advanced techniques for rapid and accurate diagnosis of TB, with better performance characteristics, that can be easily implemented for routine TB diagnosis in low-resource countries.
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